Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Roy Fleischmann is a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas, USA. His research areas primarily focus on rheumatoid arthritis and osteoarthritis, investigating therapeutic efficacy and safety through various clinical studies. Recent articles authored by Professor Fleischmann explore the efficacy of novel treatments, long-term outcomes of therapies, and the associated risks of inflammation-related drug responses.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Gerd-Rüdiger Burmester

Senior Professor

Charité - Universitätsmedizin Berlin

GERMANY

View details

Tom Huizinga

prof

Leiden University Medical Center

NETHERLANDS

View details

Andrea Rubbert-Roth

Prof Dr

Kantonsspital St. Gallen

SWITZERLAND

View details

Peter C. Taylor

UNITED KINGDOM

View details

Zoltán Szekanecz

University of Debrecen

HUNGARY

View details

Bernard Combe

Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments

University of Montpellier

FRANCE

View details

vibeke strand

Adjunct Clinical Professor

Stanford University School of Medicine

UNITED STATES

View details

Ronald van Vollenhoven

Professor and Chief

Amsterdam UMC

NETHERLANDS

View details

patrick durez

UCLouvain

BELGIUM

View details

Eric Morand

MONASH UNIVERSITY

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Roy Fleischmann

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

Have we found a true disease-modifying osteoarthritis drug (DMOAD) or is there still much work to be done?

Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician

TYK2: an emerging therapeutic target in rheumatic disease

Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Is there a role for vagal nerve stimulation in the treatment of rheumatoid arthritis?

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis

Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Collaborators (10)

Gerd-Rüdiger Burmester

Tom Huizinga

Andrea Rubbert-Roth

Peter C. Taylor

Zoltán Szekanecz

Bernard Combe

vibeke strand

Ronald van Vollenhoven

patrick durez

Eric Morand

Make your next move.